BioSpace News Archive

NANOBIOTIX announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology featuring potential first-in-class radioenhancer NBTXR3 in combination with concurrent chemoradiation for the treatment of head and neck cancer and rectal cancer.

InnoCare Pharma, a leading biotech company, announced that Professor Zhanguo Li, the leading PI, has presented latest data of BTK inhibitor orelabrutinib for the treatment of Systemic Lupus Erythematosus at the just-concluded EULAR 2022 European Congress of Rheumatology.

Akeso, Inc. released clinical details in poster presentation featuring phase Ib/II study of its Ivonescimab in advanced non-small cell lung cancer at 2022 ASCO Annual Meeting.

Cyteir Therapeutics, Inc. presented results from a Phase 1 dose escalation monotherapy trial with CYT-0851 in a poster titled “Phase 1 Results of CYT-0851 in Patients with Advanced Solid and Hematologic Cancers” at the 2022 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

Merus N.V. announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program of the bispecific antibody Zeno in patients with NRG1+ cancer presented virtually by Lead Author, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center at the 2022 ASCO Annual meeting.

Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty real-world study show that Jardiance® was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adults with type 2 diabetes in routine care.

WuXi Biologics, a global CRDMO service company, announced it has successfully launched the GMP operation of its new drug product facility DP5 located in Wuxi, China.

OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, announced that it has closed Series B2 financing from Asahi Kasei Medical Co., Ltd.

Northwest Biotherapeutics reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company’s DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up.

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced a collaboration with Arvinas, Inc., to develop FoundationOne®Liquid CDx as a companion diagnostic for use with Arvinas’ bavdegalutamide, an investigational novel PROTAC® protein degrader targeting the androgen receptor.